The heart of tech

This article was published on May 12, 2017


Biotech company raises $360 million for cancer-detecting blood test

Biotech company raises $360 million for cancer-detecting blood test
Rachel Kaser
Story by

Rachel Kaser

Internet Culture Writer

Rachel is a writer and former game critic from Central Texas. She enjoys gaming, writing mystery stories, streaming on Twitch, and horseback Rachel is a writer and former game critic from Central Texas. She enjoys gaming, writing mystery stories, streaming on Twitch, and horseback riding. Check her Twitter for curmudgeonly criticisms.

A California-based biotech company raised $360 million to fund a new early warning system that could detect cancer with a simple blood test.

Guardant Health raised the funding for Guardant360, a blood test that measures genetic biomarkers for tumors, or a “liquid biopsy.” The blood would detect “circulating tumor DNA (ctDNA),” tiny bits of DNA a tumor releases in the blood stream at it grows. According to the National Human Genome Research Institute, ctDNA tracking is a less-invasive and safer alternative to a tumor biopsy.

The ctDNA can often be used to detect cancer as it’s growing, increasing the chances it’s caught early. The World Health Organization says early detection of cancer “greatly increases the chances for successful treatment.” Guardant, however, is attempting to gather even more information from the ctDNA, such as how cancer responds to certain treatments.

Guardant hopes to use the money to sequence one million cancer patients over the next five years, which would help the company gather more data on ctDNA to improve early detection.